A Phase I/II, Open-label Study to Evaluate the Abscopal Response and Safety of Manganese and Standard-of-care Radiotherapy/ SBRT in Subjects With Metastatic Solid Tumors or Lymphoma

Radiotherapy is a regular care for metastatic solid tumors or lymphoma, and it can induce immunogenic death of tumor cells and a stronger immune response. Sometimes, tumor regression would be observed at sites distant to an irradiated field because of the radiotherapy-induced anticancer immune responses, so-called abscopal response. Manganese has been confirmed to activate innate immune and function as anticancer immunoadjuvant in pre-clinical studies. This study is designed to assess the abscopal response and safety of combined therapy of manganese and radiotherapy in patients with metastatic solid tumors or lymphoma.

Start Date06 May 2021

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

NCT03989336

/ CompletedPhase 2IIT

A Randomized, Single-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Relapsed/Refractory Ovarian Cancer

Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in patients with relapsed/refractory ovarian cancer is unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This two-arm, phase I/II study is designed to assess the safety and efficacy of combined therapy of anti-PD-1 antibody and chemotherapy with or without Manganese priming.

Start Date23 Dec 2020

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

NCT04119843

/ CompletedPhase 3

A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment

The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.

Start Date19 Feb 2020

Sponsor / Collaborator

Ascelia Pharma AB

100 Clinical Results associated with Manganese Chloride

100 Translational Medicine associated with Manganese Chloride

100 Patents (Medical) associated with Manganese Chloride

2,187

Literatures (Medical) associated with Manganese Chloride

01 Jun 2025·Separation and Purification Technology

Regulation of electron delocalization on porous carbon/manganese-iron oxide for enhancing nonradical processes of sulfamethoxazole: Oxidation pathway and mechanism

Author: Huang, Ling ; Sun, Ao-Xia ; Feng, Yong ; Sun, Meng-Qiang ; Ying, Guang-Guo ; Chen, Zhi-Liang ; Zhong, Jie ; Wei, Hang

Transition metal oxide defect engineering can regulate the electronic properties of materials, thereby realizing nonradical reactions during catalytic processes.In this study, porous carbon/manganese-iron oxide (PC@MFO) composites with different Mn/Fe ratios were prepared via in-situ encapsulation strategy.PC@MFO exhibited superior catalytic degradation and stable recycling performance during peroxymonosulfate (PMS) activation to degrade sulfamethoxazole (SMX).After 10 min of reaction, >92% of SMX was rapidly degraded, with high selectivity, through oxidative SMX removal from a complex aqueous solutionThe kinetics of SMX degradation over different as-prepared samples were also investigated.A recycling study and regeneration treatment revealed no clear deactivation between the 1st and 6th cycles, suggesting that PC@MFO is a reusable heterogeneous catalyst for utilization in efficient oxidative SMX removal.Multiple characterization techniques and d. functional theory calculations were used to study the mechanism of SMX degradation process.Nonradical oxidation was found to be the dominant reaction in the catalytic reaction, leading to SMX degradationThis was possibly due to the highly conjugated electron delocalization induced by Mn-Fe in the O-octahedra close to the oxygen vacancies, promoting rapid charge transfer and interfacial reaction kinetics.This study expands the understanding for the activation mechanism driven by Mn-Fe spinel oxides in deep-water treatment.

01 Jun 2025·Separation and Purification Technology

Electronically regulated Mn-N site-loaded MXenes for highly efficient and selective singlet oxygen generation via PMS activation

Author: Liu, Zhen ; Yuan, Shiyu ; Zheng, Peng ; Gao, Shikun ; Yuan, Shaochun ; Chen, Yao ; Yang, Shanshan ; Zhang, Zhe ; Ji, Fangfang

In this study, a novel catalyst featuring dual-reactive sites of transition metal and nonmetal is presented, which modifies electronic polarization to enhance the selective generation of singlet oxygen (¹O₂), resulting in effective degradation of antibiotics.Using MXenes as a substrate, a structurally stable Mn-N@MXenes catalyst with controllable reactive sites was synthesized via a hydrothermal method by adjusting the content of the Mn-N precursor.The study revealed that the loading of Mn-N active sites changes the electronic structure and polarization of MXenes, resulting in asym. electronic structures and the generation of numerous oxygen vacancies.These characteristics enable the Mn-N@MXenes/PMS system to selectively generate ¹O₂ and superoxide radicals (O^•-₂), with a synergistic index of 5.77.Compared to the MXenes/PMS system, the Mn-N@MXenes/PMS system significantly boosts the degradation efficiency of ofloxacin (OFL) from 71.32% to 96.07% under optimal conditions.The results demonstrate that during PMS activation, the catalyst maintains a nearly constant degradation rate after four cycles, exhibiting excellent stability and recyclability.Furthermore, the system shows superior performance and environmental adaptability in degrading actual water matrixes and other pollutants.This study reveals electronic regulation mechanisms in catalyst design that facilitate pollutant degradation via both radical and non-radical pathways, offering new strategies for efficient degradation

01 May 2025·Water Research X

Smaller sizes of polyethylene terephthalate microplastics mainly stimulate heterotrophic N2O production in aerobic granular sludge systems

Article

Author: Liu, Yingrui ; Zhu, Tingting ; Zhao, Yingxin ; Wang, Yufen ; Lu, Qian ; Ni, Bing-Jie ; Liu, Yiwen ; Tong, Yindong ; He, Yanying

Widespread polyethylene terephthalate microplastics (PET MPs) have played unintended role in nitrous oxide (N₂O) turnovers (i.e., production and consumption) at wastewater treatment plants (WWTPs). Mainstream aerobic granular sludge (AGS) systems possess potentially strong N₂O-sink capability, which may be reduced by PET MPs stress through altering N₂O-contributing pathways, electron transfer, and microbial community structures. In this study, the effects of PET MPs with two common particle sizes of effluent from WWTPs (0.1 and 0.5 mm) on N₂O turnovers, production pathways and N₂O-sink capability were systematically disclosed in AGS systems by a series of biochemical tests and molecular biological means to achieve the goal of carbon neutrality. The results indicated that 0.1 mm PET MPs could more significantly stimulate N₂O production in AGS systems by inhibiting denitrifying metabolism, compared with control and 0.5 mm PET MPs systems. Specifically, 0.1 mm PET MPs slightly increased the relative abundance of Nitrosomonas, reducing N₂O yields via promoting the hydroxylamine (NH₂OH) oxidation pathway during nitrification. Also, 0.1 mm PET MPs inhibited the electron transport system activities and the relative abundance of N₂O reductase, hindering N₂O reduction during denitrification. Most importantly, 0.1 mm PET MPs more apparently reduced the N₂O-sink capability based on the ratio of N₂O reductase gene and nitrite reductase gene.

News (Medical) associated with Manganese Chloride

23 Dec 2024

·www.accesswire.com

Ascelia Pharma Patent Granted in China for Second Generation Orviglance

MALMÖ, SWEDEN / ACCESSWIRE / December 23, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Chinese patent authorities have granted patent protection for the second-generation Orviglance®The new patent covers the effervescent tablet formulation of Orviglance. This formulation makes it even easier for patients and health care professionals to use the product. This patent protection until 2040 in China further strengthens the value proposition of the Orviglance franchise.ContactsMagnus Corfitzen, CEOEmail: [email protected]Tel: +46 735 179 118Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)Email: [email protected]Tel: +46 735 179 116This information was submitted for publication, through the agency of the contact persons set out above.About usAscelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.About OrviglanceOrviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results.AttachmentsAscelia Pharma Patent Granted in China for Second Generation OrviglanceSOURCE: Ascelia PharmaRelated Documents:

Phase 3Orphan Drug

17 Dec 2024

·www.accesswire.com

Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025

MALMO, SWEDEN / ACCESSWIRE / December 17, 2024 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two scientific abstracts with clinical data from the SPARKLE Phase 3 study with Orviglance have been accepted as an oral presentation and a scientific poster at the Society of Abdominal Radiology Congress, taking place from 16-21 February 2025 in Tucson, AZ, US.The two abstracts highlight the positive outcomes of the SPARKLE Phase 3 study. In the study Orviglance was shown to enhance the detection of suspected or known liver lesions, including small-sized lesions, and consistently shows positive results in visualizing lesions in both patients with hepatocellular carcinoma (HCC, primary liver cancer) and those with liver metastases. The study includes patients with severe renal impairment who currently lack an alternative to gadolinium-based contrast MRI.The abstract "Improved detection of focal liver lesions with manganese-based contrast agent in patients with severe kidney impairment: evidence from the SPARKLE study" was accepted as an oral presentation and "Hepatocellular carcinoma (HCC) and hepatic metastases: visualization with manganese-based contrast agent enhanced liver MRI in patients with severe kidney disease, evidence from the SPARKLE study" is to be presented in the abstracts section."The acceptance of these abstracts by the Society of Abdominal Radiology Congress is a key achievement. This prestigious event is renowned for being an important gathering for experts and professionals in the field of abdominal radiology, offering unparalleled opportunities for learning, networking, and showcasing groundbreaking research" says Andreas Norlin, CSO Ascelia Pharma.The oral presentation abstract will be held on Sunday February 16, 2025, from 10:43 AM and will be part of the Clinical Practice Improvement session.ContactsMagnus Corfitzen, CEOEmail: [email protected]Tel: +46 735 179 118Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)Email: [email protected]Tel: +46 735 179 116This information was submitted for publication, through the agency of the contact persons set out above.About usAscelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.About OrviglanceOrviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results.AttachmentsAscelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025SOURCE: Ascelia Pharma

Phase 3Orphan Drug

02 Dec 2024

·www.accesswire.com

Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting

MALMÖ, SE / ACCESSWIRE / December 2, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE) today presents the primary results from the Orviglance® phase 3 SPARKLE Study as an oral presentation at the world's largest radiology conference, RSNA, in Chicago.As communicated earlier, in the successful SPARKLE study, Orviglance significantly improved the visualization of focal liver lesions compared to unenhanced MRI in patients with suspected or known liver lesions and severe kidney impairment.The results were accepted as an oral presentation at the 2024 annual conference of the Radiological Society of North America, the world's largest radiology conference. The presentation was accepted in the Cutting-Edge Research category and will be presented today by Dr. Alvin Silva, SPARKLE Principal Investigator and Professor of Radiology, Mayo Clinic, Phoenix, United States.Title of presentation: SPARKLE: A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of ACE-MBCA in Patients with Known or Suspected Focal Liver Lesions and Severe Renal ImpairmentTiming of presentation: 2 Dec, 13:30-14:00 CDT, local time ChicagoContactsMagnus Corfitzen, CEOEmail: [email protected]Tel: +46 735 179 118Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)Email: [email protected]Tel: +46 735 179 116This information was submitted for publication, through the agency of the contact persons set out above.About usAscelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.About OrviglanceOrviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results.AttachmentsAscelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual MeetingSOURCE: Ascelia Pharma

Clinical ResultPhase 3Orphan Drug

100 Deals associated with Manganese Chloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04852	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Contrast agents	Japan	Meiji Seika Pharma Co., Ltd.	20 Apr 2006
Nutrition Disorders	United States	Hospira, Inc.	26 Jun 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent ovarian cancer	Phase 2	China	Chinese People's Liberation Army General Hospital	23 Dec 2020
Lymphoma	Phase 1	China	Chinese People's Liberation Army General Hospital	06 May 2021
Metastatic Solid Tumor	Phase 1	China	Chinese People's Liberation Army General Hospital	06 May 2021
Advanced Bile Duct Carcinoma	Phase 1	China	Chinese People's Liberation Army General Hospital	01 Mar 2019
Locally Advanced Pancreatic Adenocarcinoma	Phase 1	China	Chinese People's Liberation Army General Hospital	01 Mar 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis